| 000 | 01884 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513111144.0 | ||
| 264 | 0 | _c19970219 | |
| 008 | 199702s 0 0 eng d | ||
| 022 | _a0091-6749 | ||
| 024 | 7 |
_a10.1016/s0091-6749(97)70297-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEssayan, D M | |
| 245 | 0 | 0 |
_aDifferential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. _h[electronic resource] |
| 260 |
_bThe Journal of allergy and clinical immunology _cJan 1997 |
||
| 300 |
_a28-37 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _a3',5'-Cyclic-AMP Phosphodiesterases |
| 650 | 0 | 4 |
_aAllergens _xpharmacology |
| 650 | 0 | 4 |
_aAntigens _xpharmacology |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCyclic AMP _xmetabolism |
| 650 | 0 | 4 | _aCyclic Nucleotide Phosphodiesterases, Type 4 |
| 650 | 0 | 4 |
_aCytokines _xbiosynthesis |
| 650 | 0 | 4 |
_aGene Expression _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xdrug effects |
| 650 | 0 | 4 |
_aLymphocyte Activation _xdrug effects |
| 650 | 0 | 4 |
_aLymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aPhosphodiesterase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aPhosphoric Diester Hydrolases _xdrug effects |
| 650 | 0 | 4 |
_aPlant Proteins _xpharmacology |
| 650 | 0 | 4 |
_aPyrrolidinones _xpharmacology |
| 650 | 0 | 4 |
_aReceptors, Cell Surface _xmetabolism |
| 650 | 0 | 4 | _aRolipram |
| 650 | 0 | 4 |
_aTetanus Toxoid _xpharmacology |
| 700 | 1 | _aHuang, S K | |
| 700 | 1 | _aKagey-Sobotka, A | |
| 700 | 1 | _aLichtenstein, L M | |
| 773 | 0 |
_tThe Journal of allergy and clinical immunology _gvol. 99 _gno. 1 Pt 1 _gp. 28-37 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0091-6749(97)70297-5 _zAvailable from publisher's website |
| 999 |
_c8994343 _d8994343 |
||